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Abstract
Oxidative stress is a key mechanism causing Diabetic Nephropathy (DN). Acidic fibroblast
growth factor (aFGF) is known to confer protection from oxidative stress. However, it
also has significant angiogenic activity. Hence, we have generated a mutated human
acidic FGF (maFGF), with intact antioxidant properties but devoid of angiogenic
activities. Recent evidence shows that maFGF treatment prevented diabetic
cardiomyopathy and further in vitro studies suggest that this prevention is mediated by
suppression of cardiac oxidative stress, hypertrophy and fibrosis. We hypothesized that
maFGF treatment has a protective effect in DN.
We show that maFGF treatment did not affect body weight and blood sugar levels in a
type 1 diabetic mouse model. However maFGF prevented renal functional alterations in
diabetes and decreased renal hypertrophy following long-term diabetes. maFGF also
prevented diabetes–induced DNA damage, upregulation of angiotensinogen, oxidative
stress marker heme oxygenase 1, and alteration of endothelial nitric oxide synthase
(eNOS). Surprisingly, it failed to prevent upregulation of the fibrogenic cytokine
transforming growth factor β1 mRNA expression. However, long term administration of
maFGF partially prevented diabetes-induced extracellular matrix proteins accumulation.
Further analyses showed similar results in high glucose-induced alterations in podocytes
and microvascular endothelial cells. Likewise, maFGF showed prevention of diabetesinduced decreased nitric oxide (NO) production and apoptosis in vivo and in vitro. These
results were consistent with the prevention of long term diabetes- induced down
regulation of eNOS enzyme. Data from these experiments suggest that the preventative
effects of maFGF treatment in DN are probably via alteration of NO production, and
indicate a potential therapeutic role of maFGF in DN.

Keywords: modified acidic FGF, acidic FGF, diabetic nephropathy, oxidative stress, nitric
oxide.
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Chapter 1: Introduction
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1.1 Diabetes Mellitus
Diabetes Mellitus (DM) is a metabolic disorder that exhibits a defective or deficient
insulin secretory response, glucose underutilization, and hyperglycemia 1. It is classified
in two major types according to its etiology: type 1 DM (insulin dependent) and type 2
DM (non insulin dependent). The etiology of type 1 DM is associated with absolute lack
of insulin, which is caused by a reduction of β cells in the pancreas due to autoimmune
reactions. It is also called juvenile diabetes as the onset of this disease is before 20 years
of age. Alternatively, type 2 DM is characterized by insulin resistance (that happens
when cells fail to use insulin properly) and sometimes is combined with an absolute lack
of insulin, mainly when the disease is advanced. This is the result of the failure of
pancreatic beta cells over time to secrete more insulin to compensate hyperglycemia in
the insulin-resistant state 2. Type 2 DM is associated with overweight or obesity and
usually appears after 30 years of age, although the trend of younger people with this
disease is increasing 1, 2, 3. There are other types of diabetes namely gestational diabetes
that occurs when pregnant women develop a high blood glucose level without having a
previous history of diabetes. This third type of diabetes usually resolves after the birth of
the baby 1.
The treatment strategy for the various types of diabetes differs, however monitoring
and control of blood glucose levels, keeping a healthy diet and regular physical activity is
equally important. In the case of type 1 DM, insulin injections are required and islet cell
transplant can be performed to patients with specific requirements. Various medications
and/or insulin can be used to treat type 2 or gestational DM: antihyperglycemic,
hypoglycemic agents and insulin sensitizers such as the family of Biguanide (metformin),
sulphonylureas (glibenclamide), Thiazolidinediones (pioglitazones) and others 3.
In type 1 and type 2 diabetes the net effect is a chronic disorder of carbohydrate, fat and
protein metabolism with resulting chronic complications affecting the blood vessels,
kidneys, eyes and nerves 1. These secondary complications, which include coronary and
cerebrovascular disorders, peripheral arterial disease, nephropathy and retinopathy, are
the main cause of the increased morbidity and mortality in the diabetic population.
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Hence, the study of the molecular pathophysiology of diabetes complications can bring
up insights for potential treatments to manage these complications.
1.2 Epidemiology
Diabetes Mellitus is one of the fastest-growing health issues in the world, affecting
around 387 million people in the planet 4. As a consequence of a life-style consisting in
lack of exercise, an unhealthy diet and overweight/obesity, DM is reaching epidemic
proportion in some regions. North America and the Caribbean is the region with higher
prevalence with an estimate of 39 million people with this disease.
According to the American Diabetes Association (ADA), the prevalence of diabetic and
prediabetic cases in the United States has increased since 2010 and diabetes remained
the seventh cause of death by the same year 5. In Canada, the overall prevalence of
diabetes has increased gradually although incidence has been stable in the last decade
6

). The relative increase in prevalence accounts mainly for Canadians in the working age

group and it is associated with overweight and obesity. This causes a burden to the
health care system as individuals with diabetes are estimated to create three to four
times more health care expenses than individuals without diabetes

5, 6

.

Some examples

include the increased risk of hospitalization with cardiovascular disease (over 3 times),
end- stage renal disease (12 times) and non-traumatic lower limb amputations (20
times) of diabetic individuals compared to non diabetic population 5, 6.
Diabetic nephropathy (DN) is one of the significant long-term complications in terms of
morbidity and mortality for individual patients with diabetes. It is estimated that about
25-40% of diabetic patients develop DN within 20-25 years of the onset of diabetes 7. In
fact, diabetes is responsible for 30-40% of all end-stage renal diseases in North America
8, 9

.
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1.3 Diabetes Nephropathy and pathophysiologic changes
Diabetic nephropathy is a clinical syndrome characterized by the following 10:


Persistent albuminuria (>300 mg/d or >200 μg/min)



Progressive decline in the glomerular filtration rate (GFR)



Elevated arterial blood pressure

At the tissue level, various cell types are involved in DN. They include glomerular
podocytes, mesangial cells and endothelial cells, tubular epithelium, and interstitial
fibroblasts 9, 11. However, similar to the other diabetic complications, DN is essentially a
microvascular disease in which endothelial dysfunction serves as a key event in its
development and progression.
Additionally, DN develops as a result of the confluence of hemodynamic and metabolic
perturbations

9,

12,

13

. The pathophysiologic changes comprise hyperfiltration,

hyperperfusion and microalbuminuria in the very early stages followed by worsening of
renal functions. This is linked with diffuse thickening of the glomerular and tubular
basement membranes, as well as mesangial matrix and tubule-interstitial compartment
expansion caused by increased deposition of extracellular matrix proteins and mesangial
cell hypertrophy. The progressive expansion of the mesangium in the later stages
restricts the capillary surface available for filtration and, as a consequence, the
glomerular filtration rate falls. In addition, another pathologic correlates are glomerular
podocyte alteration and loss. This is exhibited through effacement of foot processes and
decreased number of podocytes (detachment of podocytes from the glomerular
membrane) due to apoptosis. These changes ultimately progress to proteinuria,
glomerulosclerosis and tubulointerstitial fibrosis 9, 11-14.
1.4 Pathophysiologic mechanisms in DN
Similar to the other microvascular complications of diabetes , hyperglycemia is the major
factor which causes damage to the discussed cell types by increasing the production of
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reactive oxygen species (ROS)

9, 14, 15

. Moreover, DN is thought to result from

interactions involving metabolic and hemodynamic factors 9, 13. Hyperglycemia increases
superoxide production by the mitochondrial electron transport chain. Increased ROS
inhibits glycolysis by interfering with the activity of the enzyme glyceraldehyde-3phosphate dehydrogenase (GAPDH) impelling glucose to other pathways which also
induce oxidative stress

14

. These specific glucose dependent metabolic pathways are

activated within the endothelial cells and include increased flux of polyols and
hexosamines, increase activity of protein kinase C (PKC) and generation of advanced
glycation end products (AGE). As a result, other cellular events triggered are increased
activity of transforming growth factor β (TGF-β)- Smad-MAPK and G-proteins, altered
expression of cyclin kinases and their inhibitors, and of matrix degrading enzymes and
their inhibitors 9, 11, 12.
Hemodynamic factors implicated in DN include elevation of systemic and
intraglomerular pressure and activation of various vasoactive factors pathways including
the renin-angiotensin system and endothelins 7, 12, 13. The altered hemodynamic changes
act in concert with metabolic pathways to activate intracellular second messengers
which affect gene expression. Some of the consequences are increased prosclerotic
cytokine TGF-β1, transcription factors such as NF- κB that activates local inflammatory
responses and various growth factors such as the permeability enhancing VEGF.
Ultimately, these molecular mechanisms lead to the progression of the functional and
structural changes that lead to end stage renal failure 9, 11, 14 (Figure 1.1).
1.4.1 Oxidative stress in DN
Oxidative stress occurs when the amount of reactive oxygen species (ROS) and reactive
nitrogen species (RNS) are more than the defensive system can remove

15, 16

. In DN,

there are a number of enzymatic and non enzymatic sources of ROS including auto
oxidation of glucose, transition metal-catalyzed Fenton reactions, advanced glycation
end products formation, polyol pathway flux, mitochondrial respiratory chain

6

Figure 1.1 Scheme of the Pathophysiological mechanisms of DN. Metabolic and
hemodynamic processes are induced by hyperglycemia and act in concert activating
different pathways with altered expression of genes and cellular dysfunction. Oxidative
stress from ROS and RNS generation is enhanced by hyperglycemia-induced metabolic
and hemodynamic processes and is important for the formation of mediators causing
structural alterations and functional damage (Figure adapted from reference # 13).
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deficiencies, xanthine oxidase activity, peroxidases, nitric oxide synthase and (NADPH)
oxidase 15. The mitochondrial respiratory chain is thought to be a major source of excess
ROS in diabetes in response to hyperglycemia and a key initiator for the pathogenic
pathways

14, 15

. Furthermore, a number of functional enzymes within the mitochondria

are particularly susceptible to ROS mediated damage, leading to altered ATP synthesis,
cellular Ca2+ dysregulation, and induction of mitochondrial permeability transition, all of
which predispose the cell to necrosis or apoptosis 15.
In addition, overproduction of superoxide has shown to be associated with endothelial
dysfunction by activating proinflammatory signals and inactivating important enzymes
involved in vascular homeostasis such as endothelial Nitric Oxide Synthase (eNOS) 17, 18.
Therefore, oxidative stress suppresses Nitric Oxide (NO) bioavailability which increase
generation of ROS and lead to oxidative damage to lipids, proteins, aminoacids and DNA
17

. This decreased NO bioactivity is also thought to be due to quenching by increased

ROS production. NO is inactivated through its reaction with ROS to form peroxynitrite
(ONOO-) which is toxic and exhibits direct oxidative reactivity. Hence, the rate of NO
production and its reactivity relies on the rates of ROS generation in the tissues 17.
1.4.2 Nitric Oxide and endothelial dysfunction in DN
Nitric Oxide is considered the single most important factor for maintaining vascular
endothelial function and vascular tone relaxation

17, 19

. Several studies have shown that

NO produced by endothelial cells through eNOS plays a major role for maintaining
vascular function and homeostasis, and that decreased NO production and
bioavailability in effect contribute to endothelial dysfunction in diabetes

17, 20-21

.

Moreover, the development and progression of DN is associated with alterations in
eNOS expression and activity

17, 22

. The fact that lack of eNOS can contribute to both

glomerular and tubulointerstitial fibrosis suggests that disruption of NO signaling in the
kidney may be a major factor in the development of DN 17.
Nitric Oxide is a gaseous free radical molecule which is synthesized by the action of the
enzymes Nitric Oxide Synthase (NOS) using as substrate L-arginine and yielding L-
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citrulline. It plays several physiological roles in the kidney, including control of renal and
glomerular hemodynamics, promoting natriuresis and diuresis, and renal adaptation to
dietary salt intake

23

. There are three different isoforms of NOS: endothelial (eNOS),

neuronal (nNOS) and inducible (iNOS) enzymes, and the three are present in the kidneys
20, 21

. The eNOS isoform was shown to be the major NOS enzyme in renal vasculature,

nNOS is more abundant in the macula densa whereas iNOS is weakly expressed in the
kidney 23, 24.
The eNOS enzyme is only fully functional in a dimeric form and the functional activity of
the dimer depends on the level of tetrahydrobiopterin (BH4), a cofactor for NOS enzyme
17, 21-25

. Under physiological conditions eNOS exists as a dimer and produces NO but the

enzyme reduces oxygen to superoxide anion when there is decreased availability of BH4.
Additionally, the uncoupling of eNOS induced by oxidation of the enzyme zinc-thiolate
cluster by small amounts of ONOO- decreases NO synthesis and increases superoxide
anion production by the enzyme

17

. Diabetes is associated with eNOS uncoupling and

decreased BH4 levels due to its oxidation by ROS. This condition promotes further
oxidative stress and decreased NO bioavailability

17, 25

. Indeed, uncoupling of eNOS is

one of the pathways identified as potentially major contributors of the pathogenesis of
diabetic kidney disease 15.
Dysregulation of NO has been described in patients with DN, including increased eNOS
activity early after the onset of diabetes, with augmented basal NO release which might
explain intrarenal vasodilation and hyperfiltration seen in this first stage. Prolonged
diabetes is associated with downregulation of glomerular or renal eNOS expression
which leads to NO deficiency that may facilitate the progression of DN 20, 21, 26. The other
isoforms nNOS and iNOS are expressed variably in diabetic kidneys 24.
Additionally, in vitro studies have evidenced that hyperglycemia reduces eNOS activity
and/or NO bioavailability in endothelial cells leading to decreased endothelial cell
survival and endothelial dysfunction 11, 19. Also, the combination of eNOS deficiency and
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hyperglycemia leads to podocyte injury

26

. In fact, eNOS deficiency by itself provokes

profound effects on podocyte integrity and leads to albuminuria 12, 26.
Increased evidence shows the cross-talk between glomerular endothelial cells and
podocytes through the secretion of cytokines and growth factors. This cross-talk can
influence the behaviour of the glomerular filtration membrane and the susceptibility for
the development and progression of kidney disease 27. Indeed, there is evidence that the
severity of DN lesions and renal function in type 1 diabetic patients is associated with
reduction of glomerular endothelial cells fenestration and increase in podocyte
detachment 28.
Accordingly, the understanding of the mechanisms and mediators involved in the
pathophysiology of DN including the communication between the cells in the kidney is
an important action to tackle the development of new potential therapies in order to
prevent early complications.
1.5 Therapeutic strategies in DN
The major therapeutic strategies involved in the management and prevention of DN
have included intensified glycaemic control and antihypertensive agents particularly
those which interrupt the renin-angiotensin system such as angiotensin receptor
blockers (losartan or irbesartan) 12, 13. Recently, novel strategies have been under clinical
investigations and include inhibitors of AGEs, inhibitors of metabolic pathways such as
specific PKC isoforms or the enzyme aldose reductase, or inhibitors of vasoactive factors
29

. All of these targeted pathways seem to have a common mechanism as they are

triggered by oxidative stress, and some contribute to enhance the oxidative stress inside
the cells. It is predicted that multiple therapies will be required to reduce the
progression of DN.
Considering that hyperglycemia-induced oxidative stress plays such an important role in
the pathogenesis of diabetic complications, the investigation of new molecules with
preventative effects or protective action against oxidative stress may be a wise adjuvant
therapy required to further optimize renoprotection in diabetes. Some molecules that
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have conferred protection to the cells from oxidative damage are the acidic and basic
fibroblast growth factors (aFGF, bFGF).
1.6 The acidic and basic Fibroblast Growth Factors
The aFGF (or FGF1) and bFGF (or FGF2) belong to a large family of heparin-binding
growth factors (polypeptides) that has 23 members to date. Both are considered
prototype members of this family and are closely related molecules: they have 53 %
sequence homology, interact with the same receptor and posses mitogenic properties
toward fibroblasts and endothelial cells

30, 31, 32

. They can affect differentiation,

migration and survival of many cell types, playing an important role in the control of
nervous system, wound healing and in tumor angiogenesis. FGFs mediate their cellular
responses by binding to and activating a family of 4 receptor tyrosine kinases. These
peptides are located in the ECM, bind to heparin or heparan-sulfate proteoglycans which
act as an accessory molecule that regulate FGF-binding and the activation of the
occupied signaling receptors 30-33.
The four isoforms of the receptors (FGFR1-4), encoded in four different genes, are
generated by alternative splicing of FGFR transcripts 33. The activation of these receptors
initiates further downstream signaling by mitogen-activated protein kinase (MAPK),
phosphatidilinositol-3 kinase (PI-3K) and phospholipase C 31-33. This signalling is mediated
via direct recruitment of signalling proteins that bind to tyrosine auto-phosphorylation
sites on the activated receptor and, via closely linked docking proteins (that become
tyrosine phosphorylated in response to FGF-stimulation), form a complex with additional
complement of signaling proteins

33

(Figure 1.2). The receptors seem to mediate

activation of the same targets and differ only in the strength of their tyrosine kinase
activity. Furthermore, they have different abilities to mediate the translocation of
external FGF to the cytoplasm and nucleus, which appears to be due to variation in their
C-terminal tail. As a result, FGFR1 and FGFR4 are able to mediate translocation whereas
FGFR2 and FGFR3 lack this ability

34

. It has been shown that this translocation to the
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nucleus determines the mitogenic activity of FGFs since it is a necessary condition to
activate DNA synthesis and proliferation 35, 36 (Figure1.2).
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Figure 1.2 Diagram depicting signaling pathways downstream of FGFR-1 upon tyrosine
phosphorylation. Besides the activation of the downstream signalling by MAPK
(mitogen-activated protein kinase), PI-3K (phosphatidilinositide-3 kinase) and PKC
(protein kinase C), the receptor complex is translocated to the nuclei for activation of
DNA synthesis. This is thought to be a necessary condition to induce proliferation (Figure
adapted from reference # 37).
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Some studies show that FGFs interact with the FGFRs based on its tridimensional
structure. The FGF residues interacting with the specific tyrosine kinases cluster in two
separate patches of its three dimensional structure: recognition site 1 (RS1) which seems
to be important for mitogenesis and recognition site 2 (RS2) that seems to be involved in
vasodilatory and ischemic protective actions and have a less important rate in the
mitogenic activity of the protein 38.
FGF has been found to be in an inactive form in the cytoplasm and is activated by cell
injury

33

. It is produced by endothelial cells, fibroblasts, macrophages, smooth muscle

cells, myoblasts, lens epithelial cells and osteoblasts 30, 33.
1.6.1 The aFGF and bFGF as non-mitogenic and pleiotropic peptides
FGFs are implicated in a wide range of pathological conditions such as tumorigenesis and
metastasis, mainly due to its potent angiogenic activity. In the context of diabetic
complications, bFGF has been reported to contribute to the glucose-induced vascular
dysfunction

39

, and is upregulated in diabetic retinopathy

40, 41, 42, 43, 44

. Particularly in

DN, there are reports of upregulated expression of bFGF with a good correlation to the
degree of renal injury 32. Furthermore, it is known that bFGF is induced in human renal
fibrosis (characteristic of DN) and induces proliferation in human renal fibroblasts after
activation by TGF-β1 39.
On the other hand, there is evidence of the survival effects of FGFs in the context of
oxidative stress. As these peptides are multifunctional, multiple studies are based on
the nonmitogenic properties of FGFs in differentiated cells. In the retina, basic FGF has
been found to augment endothelial cells’ resistance to oxidative stress
recovery from ischemia and reperfusion injury in brain and kidney

45

46,47

and improves

. In the heart,

aFGF has attenuated tissue damage after myocardial ischemia followed by reperfusion
48

, and has shown protection on ischemic kidney, liver and gut injuries 49.
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The FGFs can also produce vasoactive responses as confirmed in some studies where
aFGF and bFGF were found to induce vasodilation in microvessels indicating that FGFs
are able to stimulate endothelial NOS expression and subsequent synthesis of NO
52

50, 51,

. These results are evident not only in endothelial cells but in smooth muscle cells and

some types of cancer cells, and may be associated with the survival actions of FGFs 51, 52,
52, 53, 54

.

However such potential therapeutic applications have been limited due to the presence
of the mitogenic property of these molecules. Hence, the use of a non-mitogenic form of
FGF would potentially avoid undesirable proliferative effects observed with the native
mitogenic proteins.
1.6.2 The modified human aFGF
Considering the various functions of FGFs, some modifications have been done to the
native FGF molecule to uncouple the mitogenic activity from the vasodilatory and
antiapoptotic actions 38, 47, 55, 56, 57, 58, 59, 60, 61. Although the primary translation product
for aFGF is a 155 aminoacids protein, it could result in polypeptides of 134, 140 or 154
residues due to specific proteolytic cleavages 62, 63 . Several studies have also been made
with non mitogenic human acidic fibroblast growth factor (nhaFGF; nm-aFGF),
recombinant human acidic FGF (FGF28-154) or modified human acidic FGF (maFGF),
which are devoid of mitogenic activity and show potent antiapoptotic actions 38, 55, 57-61.
The mutated aFGF has been generated by deleting the sequence of the first 27
aminoacids near the NH2-terminus (FGF28-154)

57

. This modification suggests that the

lack of mitogenic activity of this polypeptide derives from the alteration of the RS1
tridimensional structure. Moreover, this change is considered to confer instability to the
maFGF to successfully interact with the receptor. This mutated domain has the role to
maintain the structural integrity of aFGF required for optimal binding to and activation
of the transmembrane receptor complex

38, 64

. The truncated protein does not induce

cell division even though it is recognized by the cell membrane receptor, triggers the
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early mitogenic events, and retains the neuromodulatory, vasoactive, and cardio- and
neuroprotective properties of the native full-length molecule 38.
Recent studies using maFGF have shown cardiovascular protection from oxidative stress
in vitro and in vivo

58

and protection from the cytotoxic effects of hydrogen peroxide

treatment in cultured cardiomyocytes

59

. The effects of ischemia/reperfusion- induced

cardiac dysfunction and tissue damage were significantly attenuated in rats with in-vivoadministered maFGF

48

. Similar results were obtained in cerebral ischemia/reperfusion

injury which was prevented by the same treatment 59. Oxygen free radicals generation is
one of the mechanisms responsible for ischemia-reperfusion damage. Moreover, some
of these studies reveal that the protective effect of the maFGF is associated with
increase in cellular antioxidant activity

59, 60

. Additionally, the maFGF treatment has

shown prevention of diabetic cardiomyopathy 61. These latter results suggest protection
through attenuation of cardiac oxidative stress, hypertrophy, and fibrosis.
Since hyperglycemia-induced oxidative stress plays an important role in the
pathogenesis of DN, we hypothesize that maFGF prevents kidney damage in DN.
1.7 Rationale
Metabolic changes in DN induce oxidative stress that triggers the activation of
pathological mechanisms which lead to dysfunction of endothelial cells and glomerular
visceral epithelial cells and eventually apoptosis. Since modified aFGF is a non-mitogenic
form of FGF that has antiapoptotic and protective actions from oxidative damage in
tissues, it is possible that it could preserve the functionality of these cells and prevent or
attenuate DN. The role of FGFs in diabetic nephropathy is not very well defined; hence
the study of the maFGF could shed light to the possible ways that the native FGF exerts
its actions in the metabolic changes in DN, granting further importance to this study.
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1.8 Hypothesis
The study is based on the hypothesis that modified aFGF treatment has a protective
effect in diabetic nephropathy

1.9 Specific Aims
In order to test this hypothesis we formulated two specific aims.
Aim 1: To investigate the effects of the maFGF on the biochemical, functional, and
structural changes in the kidneys of type 1 diabetic mice.
Aim 2:

To investigate the effects of the maFGF action in preventing glucose induced

alterations in vitro.
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2.1 In vivo studies
Groups of male FVB mice 8-10 weeks of age (Jackson Laboratory, Bar Harbor, Maine)
received intraperitoneal injections of streptozotocin (STZ) (Sigma-Aldrich, St Louis, MO)
dissolved in 0.1M sodium citrate (PH 4.5) at 50 mg/Kg body weight daily on 5
consecutive days. Control mice received multiple injections of the same volume of
sodium citrate buffer. Five days after the last injection of STZ, the blood glucose was
measured. Mice with hyperglycemia (blood glucose levels 250 mM/dL) were defined as
diabetic. Groups of control and diabetic mice were also subjected to treatment
(intraperitoneal (IP) injections) with or without maFGF (produced by our collaborators
using gene engineering) (10µg/Kg) every day for 1 month or for 6 months. Animals were
monitored for body weight and blood glucose weekly and urine was collected before the
end of the experiment. After each time point, animals were sacrificed and plasma,
serum and kidney tissues were collected.
Production of maFGF:
Generation of the maFGF (aFGF28-154) has been previously described 57. Briefly, it was
generated by amplification of appropriate DNA fragments followed by subcloning the
products into pET vectors. The vectors were expressed in BL21 (DE3) cells (strain of E.
coli) and purified on an M2 agarose affinity column. The powder form was then
reconstituted in PBS and stored in -80°C until needed.
2.2 In vitro studies
2.2.1 Human microvascular endothelial cells (HMVEC):
Dermal-derived human microvascular endothelial cells (HMVECs) (Lonza Walkersville,
MD) were cultured in EBM-2 media containing 5mmol/L D-Glucose, 10% fetal bovine
serum (FBS) (Sigma-Aldrich, Oakville, ON) and necessary supplements provided in EBM2
single kits. Cells were grown and maintained in a humidified atmosphere containing 5%
CO2 at 37 °C. At 80% confluence, cells were arrested in serum-free media with no growth
factors overnight, before incubation with glucose (25mmol/L). The experiments were
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performed after 24 or 48 hours of glucose incubation with or without maFGF 1 hour pretreatment, at the dose 200ug/ml or aFGF (200ug/ml) as positive control. These doses
were chosen based on previous experiments performed in our lab with HMVEC. For
some experiments, 500 μmol/L of N-nitro-L-arginine methyl ester hydrochloride (LNAME) (Sigma-Aldrich), an inhibitor of NOS, was added to the serum-free media when
cells were arrested. Osmotic controls were also used where necessary (20mmol/L Lglucose + 5mmol/L D-glucose). All experiments were performed with 3 to 5 replicates.
2.2.2 Podocytes (E11 cell line)
The E11 cell line, conditionally immortalized mouse podocytes were obtained (CLS
Eppleheim Germany), and was handled as described

42

. The growing cells were

maintained under permissible conditions: in RPMI 1640 media (Life technologies)
supplemented with 50 units/ml mouse recombinant- interferon Ɣ (Prospec Protein
Specialists), 100 units/ml of penicillin/streptomycin and 100 units/ml of antimicotic in
collagen-coated flasks at 33°C. When the cells reached 60% confluence, they were
passage and allowed differentiating under non permissive conditions before any
experimental manipulation: at 38°C for 14 days without interferon Ɣ in RPMI 1640
media. Podocyte differentiation was confirmed by expression of Synaptopodin (mRNA
expression) (Sigma-Aldrich). When confluent, cells were arrested overnight in RPMI1640 serum-free media containing 0.2% BSA before incubation with glucose (30mmol/L).
The experiments were performed similar to HMVEC. The dose used for maFGF and the
native aFGF treatment was 20ug/ml, chosen after dose-response experiments
conducted with 5ug/ml, 10ug/ml and 20ug/ml.
2.3 RNA extraction and real-time PCR
RNA isolation was done using the Trizol reagent (Invitrogen Burlington, Canada)
following the protocol established in our lab. RNA was extracted with 0.2 ml chloroform
added to the trizol. Following centrifugation at 15000 x g for 15 mins at 4°C, the aqueous
phase was separated from the organic phase and placed in a fresh tube. RNA was
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recovered from the aqueous phase by isopropyl alcohol precipitation using equal
volume of the aqueous phase. The samples were vortexed and centrifuged at 15000 x g
for 15 mins at 4°C and the pellet was washed with 75% ethanol in diethylpyrocarbonate
(DEPC) -treated water and dried. The total RNA was suspended in 15 ul DEPC water and
the concentration was quantified with spectrophotometry at 260 nm (Gene Quant,
Pharmacia Biotech, USA). Total RNA (2 ug) was used for cDNA synthesis with high
capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, USA). Real-time
RT-PCR was performed by using the LightCycler 96 (Roche Diagnostics Canada, Laval QC)
and SYBR Green detection (Clontech, Mountain View, USA). According to the
manufacturer’s protocol, for a final reaction volume of 20 uL the following reagents
were added: 10 uL SYBR Advantage qPCR Premix, 1 uL each of forward and reverse
primers (10 mmol/L), 7 uL H2O, and 1 uL cDNA template. Primers for mouse or human βactin, ANG, TGFβ-1, eNOS, iNOS, FN, Col4α1, VEGF, Bcl-2 and Bak-1 are listed in table 2.1
(Sigma-Aldrich) and HO1 were obtained (Qiagen, Germantown, MD). The mRNA levels
were quantified by using the standard curve method. Standard curves were constructed
by using a serially diluted standard template. The data was normalized to β-actin
ribosomal RNA to account for differences in reverse transcription efficiencies and the
amount of template in the reaction mixtures.
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Table 2.1 Oligonucleotide sequences RT-PCR
Gene
β-actin (mouse/human)
VEGF (mouse/human)
Col4α1 (mouse)
FN (mouse)
TGFβ-1 (mouse)
iNOS (mouse)
eNOS (mouse)
ANG (mouse)
Bak1 (mouse)
Bcl-2 (mouse)
Synaptopodin (mouse)
Col4α1 (human)
FN (human)
TGFβ-1 (human)
eNOS (human)
ANG (human)
Bak1 (human)
Bcl-2 (human)

Primer sequences (5’-3’): Forward
Reverse
CCTCTATGCCAACACAGTGC
CATCGTACTCCTGCTTGCTG
GGCCTCCGAAACCATGAACTTTCTGCT
GCATGCCCTCCTGCCCGGCTCACCGC
ACAGGCACAAGTTAGGAAA
ATCTCCTTTCTCTCCCAAG
CGGTGTTTTTTACGGGAGTTTC
GCGCACACACTCGCACACACG
GGACTCTCCACCTGCAAGAC
GACTGGCGAGCCTTAGTTTG

CTGGCTCGCTTTGCCACGGA
GCTGCGACAGCAGGAAGGCA
TTGGCGGCGCAAGAGGAAGG
TCTCGGGCAGCAGCTTTGGC
CACCCCTGCTACAGTCCATT
GTCTGTACTGACCCCCTCCA
CATCCACCACCATGAATCCAC
CTCCAGATGTGGGATGGCTC
CCTGTGGATGACTGAGTACC
GAGACAGCCAGGAGAAATCA
TTGCTTAGGGCGCTGAGTGG
CTCCTTCAGGTCGTTTTCGGT
CAAGAGGATTTCCAGGTCCA
TCATTGCCTTGCACGTAGAG
GATAAATCAACAGTGGGAGC
CCCAGATCATGGAGTCTTTA
CAACAATTCCTGGCGATACC
CGAAAGCCCTGTATTCCGTCTCC
TCGACCCAGGATGGGCCCTG
CGTCACGGGGTTTCTGGGGC
GCAGATAACAACCCCGGACA
TGCAGGCTTCTACTGCTCAC
GGGGTGTAGATGGGGGAACT
GGGTGAGGGGATTGCACAGTTTA
TTGCTTTACGTGGCCTGTTTC
GAAGACCCTGAAGGACAGCCAT
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2.4 Measurement of renal parameters
The albumin excretion was measured after 1 month and 6 months of the onset of type 1
diabetes and normalized in relation to creatinine in order to measure renal function.
Urinary albumin was measured using the murine microalbuminuria ELISA kit (Albuwell
Philadelphia, PA) following the manufacturer’s protocol. Mouse urine was collected by
placing the animals in a metabolic cage for 24 hours before the animals were
euthanized. The collected urine was stored at -80oC for future use. Urine concentration
for each sample was diluted relative to the standards before performing the assay.
Duplicate samples, controls and standards were incubated with Rabbit Anti-murine
Albumin Antibody for 30 minutes (primary incubation). After 10 wash cycles with wash
buffer (provided by the kit), the test plate was incubated with Anti-rabbit HRP conjugate
for 30 minutes (secondary incubation). The color development was obtained after
washing the plate and adding the chromogenic substrate. After 5-10 minutes, the color
stopper was added to each well to terminate the color reaction. The plate was then
examined in a Multiskan FC Microplate Photometer (Thermo Scientific, Finland) to
determine the absorbance at 450nm.
The determination of creatinine was done using a Creatinine Companion kit (Albuwell
Philadelphia, PA) to normalize albumin in relation to creatinine. The same specimens
used for the albumin quantification were used for creatinine determination following
the manufacturer’s protocol. The procedure uses an adaptation of the alkaline picrate
method and requires determination of the differential absorbance in a sample before
and after the addition of acid to correct for color generation due to interfering
substances. Hence, the absorbance was determined on the plate reader at 500 nm in
two different time points: 10 minutes after adding the picrate working solution and 5
minutes after adding the acid reagent.
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2.5 Protein extraction and ELISA
Kidney tissues were washed with cold phosphate buffered saline (PBS) and homogenized
in 0.4 ml RIPA lysis buffer (Upstate, Temecula CA) with a micro tissue grinder on ice.
Homogenates were centrifuged for 5 minutes at 5000 rpm and the supernatant was
aliquot and stored or used for the assay. The total protein concentration was measured
using BCATM protein assay kit (Pierce, Rockford, IL, USA) according to the manufacturer’s
instructions. The concentrations of all samples were adjusted before performing ELISA.
We performed FN (Kamiya Biomedicals, WA, USA) and Col1 α(IV) (Cloud- Clone Corp, TX
USA) protein measurement following the manufacturer’s protocols.
2.6 Cellular reactive oxygen species levels
Intracellular ROS generation was assessed using a dichlorofluorescein diacetate (DCFDA)
Cellular ROS Detection Assay kit (Abcam Toronto, ON) according to the manufacturer’s
instructions. Podocytes were seeded 2.5x104 cells per well on a dark 96 well microplate,
they were allowed to adhere overnight. The next day, cells were starved overnight by
replacing the media with serum-free media. On the following morning, cells were
incubated with high glucose (25mmol/L) for 48 or 72 hours with or without maFGF one
hour pre-treatment at the dose 20μ/ml or aFGF (20μg/ml) used as positive control. At
both time points, the cells were incubated with DCFDA solution for 30 minutes at 37oC in
the dark. Plate was read in a Gemini Fluorescence Microplate Reader with excitation
wavelength at 485 nm and emission wavelength at 535 nm. The data generated as ratio
of the relative fluorescence intensity of control and treated wells to the relative
fluorescence intensity of the blank wells. Data were normalized respective to percentage
of number of cells.
2.7 Antioxidant enzymes activity
Catalase and Glutathione Peroxidase activities were assessed through a Catalase assay
kit and a Glutathione Peroxidase assay kit (Cayman Chemical Ann Arbor, MI) following
the manufacturer’s instructions. Tissue was homogenized on ice in 5 ml of cold buffer
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consisting in 50mM potassium phosphate, ph 7.0, containing 1mM EDTA. The
homogenates were centrifuged for 15 minutes at 8000 rpm at 4oC. The supernatant was
aliquot and used for the assays on the same day or stored at -80oC. Catalase activity was
expressed as nmol of formaldehyde produced per minute in the presence of H2O2.
Glutathione peroxidase activity was expressed as the amount of enzyme that caused the
oxidation of 0.1 nmol of NADPH to NADP+ per minute. Both enzymes activity were
reported respective to ug of proteins.
2.8 NO Assay
Total Nitric Oxide production was measured in kidney tissue homogenates and cell
lysates using a fluorometric nitric oxide assay (Abcam, Toronto Ontario). The total
concentration of nitrite and nitrate was used as a quantitative measure of NO
production. The enzyme cofactor working solution for Nitrate Reductase was added to
the wells followed by the addition of Nitrate Reductase. In this step nitrate is converted
to nitrite. The plate was incubated at room temperature for 2 hours. Afterwards,
enhancer was added and incubated for 30 minutes to quench interfering compounds.
The fluorescent probe DAN (2, 3-diaminonaphthalene) that reacts with nitrite, was
added and incubated for 10 minutes followed by the addition of NaOH for 10 minutes to
increase the fluorescent field. The plate was read in a Gemini Fluorescence Microplate
Reader with excitation wavelength at 360 nm and emission wavelength at 450 nm.
2.9 TUNEL Assay
Apoptotic assays were performed by Terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL) reaction using In Situ Apoptosis Detection Kit (Takara Bio
Inc). Podocytes were cultured on eight-chamber tissue culture slides and incubated for
48 hours with the presence of glucose (25mmol/L) and maFGF (20μg/ml), aFGF
(20μg/ml) was used as positive control. The cells were counterstained with DAPI for
nuclear staining.
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For tissues embedded in paraffin, deparaffinization and rehydration (using xylene and
ethanol dilutions) was performed. The sections were treated with proteinase K (20
mg/L) for 15 min and then incubated with the TUNEL reaction mixture containing
terminal deoxynucleotidyl transferase (TdT) and digoxigenin-11-dUTP for 1 h. The TdT
reaction was carried out in a humidified chamber at 37°C. For the negative control, TdT
was omitted from the reaction mixture. Apoptotic cell death was quantitatively analyzed
by counting the TUNEL-positive cells selected randomly from 10 fields. Microscopic
observation was performed by an examiner unaware of the identity of the sample, using
a Zeiss LSM 410 inverted laser scan microscope equipped with fluorescein, rhodamine,
and DAPI filters (Carl Zeiss)
2.10 Western Blotting
Kidney tissues or cell extracts were sonicated and lysed in 0.4 ml or 0.1 ml RIPA (Upstate,
Temecula CA) lysis buffer respectively. The tissue and cell extracts were centrifuged at
3000 rpm at 4°C for 30 minutes to remove cell debris. The total protein concentration
was measured using BCATM protein assay kit (Pierce, Rockford, IL, USA) using BSA as
protein standard. Proteins were electrophoresed through a 10% SDS-PAGE gel before
transferring to a PVDF membrane. After blocking for 30 minutes at 4°C in blocking buffer
(3% BSA in PBS with 0.1% Tween 20), the membrane was incubated overnight with
mouse anti-eNOS (1:1000) or mouse anti-peNOS (1:1000) (Santa Cruz Biotechnology,
Inc). The membrane was washed and incubated for 30 minutes at room temperature
with a goat anti-mouse antibody conjugated with HRP. After further washing, the
membrane was detected with ECL kit (Amersham Pharmacia Biotech, Arlington, IL, USA).
β-actin was used as an internal controls and detected by rabbit anti- β-actin antibody
conjugated with HRP. Western blotting images were captured by Kodak 4000 mm and
density of the bands was quantitated by using ImageJ
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2.11 Cell Viability Assay
To determine the effects of maFGF treatment in the proliferation of HMVEC, the WST-1
Cell Viability Assay (Roche) was used. Cells were seeded (aprox. 5 x 104/well) onto a 96well plate and were allowed to attach overnight. Starting on the following day, cells
were starved overnight by replacing the media with serum-free media. The next
morning, maFGF (200ug/ml) was added to the wells for 6, 20, 24 or 48 hours. After each
time point, 10μL of WST-1 reagent was added to each well and the plates were
incubated for 1 hour at 37°C to produce a colour reaction. Absorbance was measured in
a Multiskan FC Microplate Photometer (Thermo Scientific, Finland) at 450nm with a
reference wavelength of 690nm.
2.12 Immunofluorescence
HMVECs cells were plated on eight-chamber tissue culture slides and incubated for 48
hours with the presence of glucose (5 mmol/L, 25mmol/L) and maFGF (200μg/ml) or
aFGF (200μg/ml), then these cells were fixed with ethanol for staining with 8-OHdG
antibody (Santa Cruz Biotehnology, Dallas). Goat IgG labeled with FITC (Vector
Laboratories, Burlingame, CA) was used for detection of the fluorescence. Slides were
mounted in Vectashield fluorescence mounting medium with 4, 6-diamidino-2phenylindole (DAPI; Vector Laboratories, Burlingame) for nuclear staining. Microscopic
observation was performed by an examiner unaware of the identity of the sample, using
a Zeiss LSM 410 inverted laser scan microscope equipped with fluorescein and DAPI
filters (Carl Zeiss)
2.13 Immunohistochemistry
Formalin-fixed tissues embedded in paraffin were sectioned at 5 μm thickness on
positively charged slides. The kidney tissues were analyzed for 8-hydroxy-2deoxyguanosine (8-OHdG) (Chemicon International Inc. CA, USA). The chromogen 3,3diamino benzine (Sigma-Aldrich) was used for detection. Non-immune horse serum was
used as a negative control. 8-OHdG immunoreactivity was assessed by the presence of
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positively stained nuclei in the glomeruli with a dark brown color. The dark brownstained nuclei were counted as a measurement of 8-OHdG immunoreactivity and the
results were expressed as percentage of positive nuclei respective to the total number
of nuclei in each glomerulus. The measurement was done in 15 glomeruli for each
sample (n=2).
2.14 Histological Analysis
Formalin-fixed tissues embedded in paraffin were sectioned at 5 μm thickness on
positively charged slides. The sections were stained with hematoxylin and eosin and
periodic acid-schiff stain (PAS). The PAS stain is used to detect extracellular matrix proteins
deposition and it gives a purple magenta color as indication of the presence of glycogen,
proteoglycans, glycoproteins and glycolipids.

2.15 Statistical analysis
Data is presented as mean ± standard error. Statistical significance of differences
between groups was tested with Student’s T-test for two groups or one-way ANOVA
with multiple comparisons (post hoc analysis) for multiple groups. A p-value of 0.05 or
less was considered to be statistically significant. All calculations were performed with
GraphPad Prism version 5.03 software.
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Chapter 3: Results
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3.1 MaFGF treatment did not affect body weight and blood glucose but decreased
renal hypertrophy following long term diabetes.
After inducing type 1 diabetes in specific groups of mice, diabetic and age-matched non
diabetic mice were divided into groups with and without treatment with maFGF
(10μg/Kg daily) for 1 month and 6 months. The body and kidney weights and blood
glucose of each group of mice were evaluated after each time point. The body weights
were not significant different among the groups at 1 month after the treatment.
However the diabetic animals showed a significantly decreased in body weight at 6
months compared to non-diabetic groups. At the same time, the blood glucose was
significantly increased in diabetic animals with or without treatment with maFGF both at
1 month and 6 months. Similarly, the ratio kidney weight- tibia length was significantly
increased in the diabetic groups at both time points which is probably result of the
hypertrophy and increased filtration area of the glomeruli as result of diabetes.
MaFGF treatment didn’t show any effects in the body weight and blood glucose
compared to the untreated diabetic group after 1 month or 6 months (Fig 3.1-A).
However, the kidney weight- tibia length ratio was significantly reduced in the diabetic
group after treatment for 6 months (Fig 3.1-B) which indicates prevention of renal
hypertrophy.
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Figure 3.1 Effects of maFGF on body weight, blood glucose levels and kidney
weight/tibia length ratio in non-diabetic and diabetic mice after (A) 1 month and (B) 6
months of treatment with maFGF. MaFGF had no effect on body weight or blood glucose
levels. However it prevented renal hypertrophy after 6 months of follow up. C: control,
maFGF: modified aFGF, DM: diabetes mellitus, DM+maFGF: diabetic treated with
maFGF.*p<0.05 vs control, # p<0.05 vs. maFGF, & p<0.05 vs. DM group.
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3.2 MaFGF treatment prevented functional damage
Microalbuminuria is an established marker for the renal dysfunction in DN. Following
onset of type 1 diabetes the glomerular filtration rate increases due to increased renal
blood flow, glomerular capillary hypertension and increased filtration surface.
Interestingly, increased excretion of albumin happens and persists along with the
declining of GFR which is the result of progressive reduction of the filtration surface
possibly due to mesangial expansion 9. We measured the albumin-to-creatinine ratio (µg
albumin/mg creatinine) which is an alternative to 24 urine collection in the detection of
microalbuminuria to assess nephropathic change. The results showed that the albuminto-creatinine ratio significantly increased in the diabetic groups. MaFGF treatment
prevented renal functional alterations in diabetes at 1 and 6 months as shown in figure
3.2.
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Figure 3.2 Effects of maFGF on albuminuria in Diabetic Nephropathy. Urinary albuminto-creatinine ratio with or without maFGF treatment at 1 or 6 months in diabetic and
non-diabetic mice. maFGF prevented diabetes induced albuminuria at both time points.
maFGF: modified aFGF, DM: diabetes mellitus, DM+maFGF: diabetic treated with
maFGF.*p<0.05 vs control, # p<0.05 vs. maFGF, & p<0.05 vs. DM group.
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3.3 MaFGF treatment prevented vasoactive factors alterations in DN.
Current evidence suggests the elevation of several vasoactive factors in early DN such as
angiotensinogen (AGT), Nitric Oxide and vascular endothelial growth factor (VEGF).
Various of these factors are also associated with elevation of systemic and
intraglomerular pressure and increased permeability 8, 9, 11. With progression of DN, the
levels of some of these factors (NO, VEGF) fall possibly due to continue endothelial
dysfunction leading to the arrest of endothelial growth and apoptosis. Results show that
maFGF treatment prevented diabetes induced alteration of the vasoactive factors
transcripts AGT, eNOS, iNOS and VEGF compared to diabetic groups (Figure 3.3). The
changes were pronounced after 6 months and maFGF treatment prevented such
changes.
The control group for the maFGF treatment didn’t show significant difference respective
to the control group (non diabetic mice) in the analysis of the transcripts or subsequent
analysis performed; therefore it was omitted from the figures.
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Figure 3.3 Effects of maFGF treatment on vasoactive factor regulation in Diabetic
Nephropathy. Quantitative RT-PCR analysis of diabetes induced mRNA expression in
mouse kidneys after 1 month and 6 months with maFGF treatment. The treatment
prevented increased production of (A) Angiotensinogen (AGT) and significantly
prevented down-regulation of (B) endothelial Nitric Oxide Synthase (eNOS), (C) inducible
Nitric Oxide Synthase (iNOS) and (D) Vascular Endothelial Growth Factor (VEGF) at the
later time point (6 months). DM: diabetes mellitus, DM+maFGF: diabetic treated with
maFGF.*p<0.05 vs control, # p<0.05 vs. DM group.
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3.4 MaFGF treatment decreased diabetes-induced oxidative stress and DNA damage in
the kidney
Development of DN is related to the induction of renal oxidative stress. We examined
the effects of diabetes-induced oxidative stress through various methods in kidney
tissue of type 1 diabetic mice. Diabetic animals showed increased HO1 transcript levels,
a marker of oxidative stress, at 1 month and 6 months after the onset of diabetes (Figure
3.4-A). Treatment with maFGF reduced the upregulation of this enzyme at both time
points. We further assessed the activity of enzymes that are activated by oxidative stress
such as Catalase (Figure 3.4-B) and Glutathione peroxidase (Figure 3.4-C). Such activity
was increased in diabetes and reduced with the maFGF treatment after 1 month and 6
months with significant difference in the case of Catalase activity. In addition, DNA
damage of kidney tissues showed increased immunohistochemical staining for 8-OHdG
(Figure 3.4-D) in the nuclei of glomeruli cells of diabetic animals and the treatment with
maFGF reduced the number of positive cells.
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Figure 3.4 Effects of maFGF treatment on diabetes induced oxidative stress. RT-PCR
analysis of diabetes induced mRNA expression for the enzyme (A) Heme Oxygenase 1
(HO1), a marker for oxidative stress, in mouse kidneys after 1 month or 6 months with
maFGF treatment. (B) Catalase (Cat) activity (expressed as nmol of formaldehyde
produced/min in the presence of H2O2 respective to μg of protein) and (C) Glutathione
peroxidase (GPx) activity (expressed as the amount of enzyme that caused the oxidation
of 0.1 nmol of NADPH to NADP+/min respected to μg of proteins) indicating that
diabetes-induced Cat and GPx activities were reduced by maFGF treatment at both time
points. DM: diabetes mellitus, DM+maFGF: diabetic treated with maFGF.*p<0.05 vs
control, # p<0.05 vs. DM group.
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Figure 3.4- (D) Effect of maFGF treatment on diabetes induced oxidative DNA damage. 8OHdG shows diabetes-induced increased positivity in the glomeruli cells and the
preventative effects of maFGF treatment versus diabetic. 8-OHdG: 8-hydroxy-2deoxyguanosine. Magnifications 60X, arrows indicate positive nuclei. n=2x15 glomeruli.
DM: diabetes mellitus, DM+maFGF: diabetic treated with maFGF.*p<0.05 vs control, #
p<0.05 vs. DM group.
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3.5 MaFGF partially prevented fibrotic response in DN
Fibrosis is one of the hallmarks of DN. The increased deposition of extracellular matrix
proteins (ECM) leads to diffuse thickening of the glomerular and tubular basement
membranes and mesangial matrix expansion. We investigated the effects of maFGF
treatment on the diabetes induced alteration of the fibrogenic cytokine TGF-β1 and
extracellular matrix proteins FN and Col 1α (IV).
The results showed that the induced fibrogenic cytokine TGF-β1 was not prevented by
maFGF treatment, as shown in the mRNA expression. However, the maFGF treatment
showed some preventive effects on alterations of the ECM protein FN and Col 1α (IV)
mRNA (Figure 3.5) and protein expression (Figure 3.6), especially when the maFGF was
administered for longer period. Histological analysis of the extracellular matrix in the
kidney through acid-Schiff stain (PAS) was performed to conclude whether these
molecular alterations produced structural changes in the organ (Figure 3.7). These stains
confirmed deposition of extracellular matrix proteins in diabetes suggestive of mesangial
expansion, as it was previously indicated by upregulated transcripts and protein
expression of Col 1α (IV). The maFGF treatment failed to prevent the fibrogenic factor
TGF-β1, although partially prevented diabetes-induced upregulation of extracellular
matrix proteins.
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Figure 3.5 Effects of maFGF treatment on diabetes induced alterations of fibrosis-related
genes. Quantitative RT-PCR analysis of diabetes induced mRNA expression for (A) the
fibrogenic cytokine TGFβ1 and extracellular matrix proteins (B) FN and (C) Col 1 α (IV) in
mouse kidneys after 1 month or 6 months with maFGF treatment. maFGF treatment
failed to prevent the fibrogenic factor TGF-β1, although partially prevented diabetesinduced upregulation of extracellular matrix proteins after 6 months. Con: control, DM:
diabetes mellitus, DM+maFGF: diabetic treated with maFGF.*p<0.05 vs control, # p<0.05
vs. DM group.
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Figure 3.6 Effects of maFGF treatment on ECM proteins expression. (A) fibronectin and
(B) collagen 1 α (IV) protein expression in non- diabetic and diabetic mouse kidneys after
1 month or 6 months with maFGF treatment. Con: control, DM: diabetes mellitus,
DM+maFGF: diabetic treated with maFGF.*p<0.05 vs control, # p<0.05 vs. DM group.
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Figure 3.7 Histologic analysis using PAS stain confirmed the molecular results indicating
that the maFGF treatment partially prevented diabetes-induced mesangial expansion
versus diabetes. Magnifications 60X, arrows indicate increased extracellular matrix
proteins deposition represented by areas stained purple magenta. 6 months samples
DM-Diabetes Mellitus, DM+maFGF-Diabetic treated with maFGF.

45

3.6 MaFGF treatment prevented high-glucose induced oxidative stress and damage
Our in vivo study showed that maFGF treatment significantly prevented functional
damage in the kidney at 1 month and 6 months and partially prevented structural
changes. We further assessed the effects of maFGF on oxidative stress as a key
mechanism causing DN; the results showed that maFGF treatment prevented diabetes
induced upregulation of the oxidative stress marker Heme Oxygenase (HO1). Moreover,
maFGF prevented diabetes-induced increased activity of the antioxidant enzymes
catalase and glutathione peroxidase and oxidative DNA damage in the glomerulus of
diabetic mice.
We further investigated how the maFGF treatment affects two of the various cellular
elements of the kidney that are targets of high glucose injury. We intended to explore
the effects of maFGF treatment in high glucose induced alteration in microvascular
endothelial cells and mouse glomerular epithelial cells (podocytes). Microvascular
endothelial cells play an important role in the pathophysiology of DN and have been
used to reproduce diabetic vascular complications in our laboratory. Podocytes are
specialized visceral epithelial cells acting as the final barrier to molecular flowing during
urine filtration. Furthermore, podocytes are closely related and in proximity with
endothelial cells in the glomeruli comprising the glomerular filtration barrier in a way
that the action of one type of cell may influence the function of the other.
Hence, we examined various parameters, consistent with those considered in vivo, in
dermal- human derived microvascular endothelial cells and podocytes. In previous
studies in our lab, it was shown that the treatment of HMVEC with maFGF prevented
high glucose-induced increase of cellular ROS levels
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. We confirmed these results

investigating oxidative DNA damage in HMVEC using the sensitive immunofluorescent
staining of 8-OHdG. The positive staining increased in HMVECs after 48-hour of high
glucose treatment (Figure 3.8). The increased 8-OHdG stain in the nucleus induced by
exposure to high glucose was significantly attenuated by treatment with both maFGF
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(200μg/ml) and the native aFGF (200μg/ml) used as positive control. The 8-OHdG
staining shown in green was co-localized with the blue of nuclear dye DAPI.
Our experiments with podocytes showed similar results for cellular ROS levels under the
same experimental conditions. After 1 hour pre-treatment of differentiated podocytes
with maFGF (20μg/ml) or aFGF (20 μg/ml) followed by 48 and 72 hours treatment with
high glucose, the upregulation of cellular ROS was significantly prevented (Figure 3.9).
Additionally, we detected mRNA expression of the enzyme HO1 in HMVEC and
podocytes. The results showed high glucose-induced significant upregulation of this
transcript which is prevented by the treatment with both maFGF and the native aFGF
after 24 and 48 hours of treatment with high glucose (Figure 3.10-A, 3.10-B).
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Figure 3.8 Effects of maFGF treatment on high glucose induced DNA oxidative damage in
HMVEC. Cells were incubated with high glucose (25 mmol/L) and maFGF (200μg/ml) or
aFGF (200μg/ml) for 48 hours. Immunocytochemistry analysis of 8-OHdG and DAPI (for
nuclear morphology) was performed using fluorescence microscopy. 8-OHdG is shown in
green (left column) and DAPI staining in blue (middle column). Images were merged
(right column). The increased 8-OHdG stain in the nucleus induced by exposure to high
glucose was significantly attenuated by treatment with both maFGF and the native aFGF.
Magnifications 60X. 8-OHdG: 8-hydroxy-2-deoxyguanosine, DAPI: 4, 6-diamidino-2phenylindole. NG: Normal Glucose, HG: High Glucose
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Figure 3.9 Effects of maFGF (20μg/ml) and the native aFGF (20μg/ml) treatment on high
glucose- induced oxidative stress in podocytes. Both native and maFGF prevented high
glucose induced increased production of cellular ROS levels. Data presented respective
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p<0.05 vs. high glucose (HG)
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Figure 3.10 Effects of maFGF or native aFGF on high glucose induced oxidative stress in
(A) HMVEC and (B) podocytes- RT-PCR analysis of mRNA expression for the enzyme
Heme Oxigenase 1 (HO1). Pre-treatment for 1 hour with maFGF or native aFGF followed
by 24 and 48 hours treatment with high glucose. Both native aFGF and maFGF prevented
high glucose induced up-regulation of HO1 mRNA expression in both cell types at both
time points. All in vitro data was obtained from at least 3 independent experiments. NG:
Normal Glucose. *p<0.05 vs. control (NG), # p<0.05 vs. high glucose (HG)
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3.7 MaFGF treatment prevented high glucose induced vasoactive factors alteration
Results in our in vivo study showed that maFGF treatment prevented diabetes induced
upregulation of AGT and downregulation of eNOS in the context of progressive diabetic
nephropathy. Therefore, we investigated the effects of maFGF which is known by its
vasodilator properties, in the expression of these factors in endothelial cells and
podocytes.
We found that podocytes express eNOS and this expression is affected by high glucose
after exposure for 48 hours similar to the high glucose induced effects in endothelial
cells eNOS expression (Figure 3.11-A). The eNOS mRNA expression is suppressed under
high glucose condition and the maFGF treatment significantly prevented high glucose
induced down-regulation of this transcript. We also tested the effects of maFGF in high
glucose induced upregulation of AGT mRNA expression in HMVEC and podocytes at 48
hours. maFGF treatment significantly prevented this alteration in both cell types (Figure
3.11-B).
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Figure 3.11 Effects of maFGF or native aFGF treatment on high glucose induced
alteration of vasoactive factors- Quantitative RT-PCR analysis of high glucose-induced
mRNA expression of (A) endothelial Nitric Oxide Synthase (eNOS) and (B)
Angiotensinogen (AGT) in HMVEC and podocytes after 1 hour pre-treatment with maFGF
or native aFGF followed by 48 hours treatment with high glucose. Both native aFGF and
maFGF prevented high glucose induced alteration of AGT and eNOS mRNA expression in
both cell types. NG: Normal Glucose. *p<0.05 vs. control (NG), # p<0.05 vs. high glucose
(HG)
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3.8 MaFGF partially prevented high glucose induced fibrotic response
MaFGF partially prevented fibrosis in our in vivo study. Hence, we examined the
expression of the fibrosis-related genes TGFβ1, FN and Col 1α (IV), under high glucose
condition in HMVEC and podocytes. The results showed that mRNA expression of these
transcripts was significantly upregulated after 48 hours (Figure 3.12). The maFGF
significantly prevented the high glucose induced upregulation of the extracellular matrix
protein transcripts FN and Col 1α (IV) in podocytes but failed to prevent the
aforementioned up-regulation in HMVEC (Figure 3.12-B, 3.12-C). Additionally, it failed to
prevent the high glucose induced up-regulation of the fibrogenic cytokine TGFβ1 in both
cell types (Figure 3.12-A).
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Figure 3.12 Effects of maFGF or native aFGF treatment on high glucose induced upregulation of fibrosis-related genes - Quantitative RT-PCR analysis of high glucoseinduced mRNA expression of (A) Transforming Growth Factor β1 (TGFβ1), (B) Fibronectin
(FN) and (C) Collagen 1α (IV) (Col 1α(IV)) in HMVEC and podocytes after 1 hour pretreatment with maFGF or native aFGF followed by 48 hours treatment with high glucose.
maFGF or native aFGF failed to prevent glucose-induced upregulation of the fibrogenic
factor TGFβ1 expression in both cells types and FN and Col 1α (IV) in HMVEC; whereas it
prevented upregulation of the later in the podocytes. NG: Normal Glucose. *p<0.05 vs
control (NG), # p<0.05 vs. high glucose (HG).
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3.9 MaFGF treatment activated eNOS enzyme and enhanced production of Nitric Oxide
in the kidney
Evidence reveals that FGFs stimulate the expression of eNOS and the production of NO
50-54

, which is known to play a key role in vascular homeostasis. Our study shows that

maFGF treatment stimulates the expression of eNOS mRNA in the kidney in the context
of diabetes induced suppression of eNOS expression. Moreover, we found similar results
in high glucose induced alterations in HMVEC and podocytes after 48 hours.
On the other hand, uncoupling of nitric oxide synthase is one of the known pathways
that generate ROS in the kidney and has been identified as potentially major contributor
to the pathogenesis of diabetic kidney disease

15, 20-23

. eNOS uncoupling leads to

production of superoxide anion rather than NO. Our in vitro study and current studies in
our lab showed that maFGF treatment prevented high glucose-induced oxidative stress
in glomerular epithelial cells and microvascular endothelial cells. maFGF also showed
prevention of oxidative DNA damage in endothelial cells. Simultaneously, our in vivo
study illustrated that maFGF treatment significantly prevented functional damage in the
kidney and had protective effects against diabetes induced oxidative stress.
To further explore the possible mechanism by which maFGF treatment exerts the
aforementioned effects, we intended to check the levels of activated eNOS protein
expression and NO production in the kidney as an indication of eNOS activity in a
coupled state. The results showed that the upregulation of eNOS mRNA in diabetic
animals treated with the maFGF was accompanied by increase levels of the eNOS
protein (Figure 3.13-A) and the 1177-serine phosphorylation status of eNOS (Figure
3.13-B). The levels of NO production, which indicate the function of eNOS enzyme in a
coupled state, were slightly downregulated in diabetic compared to the basal levels of
control. The treatment of diabetic animals with maFGF increased significantly NO
production (Figure 3.14). Furthermore, similar results were obtained in our in vitro study
which showed that under high glucose conditions for 48 hours the production of NO is
reduced significantly in both cell types: microvascular endothelial cells and podocytes
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(Figure 3.15). The treatment with maFGF restored NO production with significant
difference in the case of HMVEC.
We also examined the effects of maFGF treatment in the activation of the enzyme
producing NO by incubating the cells with L-NAME, a non specific NOS inhibitor. Under
normal conditions, the incubation of the cells with L-NAME decreased significantly the
production of NO and the treatment with maFGF restored NO production comparable to
the control group (figure 3.16)
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Figure 3.13 Western Blot analysis for total protein expression of (A) endothelial Nitric
Oxide Synthase (eNOS) or (B) serine (1177) phosphorylated eNOS in kidney tissues in
diabetic animals after 6 months of treatment with maFGF. With maFGF treatment the
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Figure 3.14 Effects of maFGF treatment in total Nitric Oxide (NO) production in kidney
tissues of diabetic animals after maFGF treatment for 6 months. The production of NO
was increased by the treatment with maFGF. maFGF: modified aFGF, DM: diabetes
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Figure 3.15 Effects of maFGF treatment in total Nitric Oxide (NO) production in high
glucose induced alterations in (A) HMVEC and (B) podocytes. Under high glucose
conditions for 48 hours the production of NO is significantly reduced in both cell types
and treatment with maFGF restored such reduction. NG: Normal Glucose. *p<0.05 vs.
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Figure 3.16 Effects of maFGF treatment in total Nitric Oxide (NO) production after
incubation with L-NAME (500 μmol/L) (an inhibitor of Nitirc Oxide Synthase enzymes) for
48 hours in (A) HMVEC and (B) podocytes. Incubation of cells with L-NAME significantly
decreased the production of NO and the treatment with maFGF restored NO production
comparable to the control group. NG: Normal Glucose, L-NAME: N-nitro-L-arginine
methyl ester hydrochloride.*p<0.05 vs. control (NG), # p<0.05 vs. high glucose (HG).
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3.10 MaFGF treatment inhibits apoptosis in diabetes
Albuminuria is often the first evidence of kidney injury in diabetes. Results from our in
vivo study illustrated that maFGF prevented functional damage in kidneys of diabetic
mice by preventing increased albumin to creatinine ratio. Urinary albumin content is
considered to reflect the underlying pathology of endothelial dysfunction and damage to
glomerular podocytes

65

. Indeed, the progression of DN correlates with podocyte loss

due to apoptosis, and hyperglycemia leads to decreased endothelial cell survival. In view
of this evidence and the prevention shown by maFGF treatment against oxidative stress
and oxidative DNA damage, we tested the possible effect that maFGF could trigger in
the apoptosis of HMVEC and podocytes under high glucose conditions. We evaluated
apoptosis through the mRNA expression of antiapopototic (B-cl2) - proapototic (Bak-1)
ratio. Results showed that, in both cell types, the ratio Bcl-2/Bak-1 was significantly
reduced under high glucose conditions (Figure 3.17). The treatment with maFGF
restored this reduction in both cases with significant difference in HMVEC (Figure 17-A).
Additionally, TUNEL assay after 6 months showed increased TUNEL positive cells (Figure
3.18). maFGF treatment of diabetic mice prevented such positivity.
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Figure 3.17 Effects of maFGF treatment on apoptosis. Quantitative RT-PCR analysis of
high glucose-induced mRNA expression of Bcl-2 (antiapoptotic)- Bak-1 (pro-apoptotic)
ratio in (A) HMVEC and (B) podocytes after 1 hour pre- treatment with maFGF or native
aFGF followed by 48 hours treatment with high glucose. maFGF or native aFGF
treatment increased the ratio Bcl-2/Bak-1 transcripts under high glucose conditions. NG:
Normal Glucose. *p<0.05 vs. control (NG), # p<0.05 vs. high glucose (HG)
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Figure 3.18 Effect of maFGF treatment in apoptosis in vivo. TUNEL assay
immunofluorescence in kidney tissue of non-diabletic and diabetic animals after
treatment with maFGF for 6 months. Diabetes-induced glomerular TUNEL positivity
(indicated with arrows) was prevented by maFGF treatment. Magnifications 40X. C:
Control, DM: Diabetes Mellitus, DM+maFGF: diabetic treated with maFGF.
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Chapter 4: Conclusions
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4.1 Discussion
4.1.1 maFGF as a potential approach to prevent Diabetic Nephropathy
Diabetes and its complications are devastating medical problems. Worldwide, there is
increased incidence and prevalence of diabetic complications. DN, one of the very
debilitating diabetic problems, commonly progresses to end stage renal disease unless
preventive strategies are implemented in the initial stages. It has been proposed that
oxidative stress is a key component in the development of DN leading to pathological
changes such as endothelial dysfunction, decreased cell survival, podocyte loss and
eventually, glomerulosclerosis and interstitial fibrosis. In view of this fact, the search of
new insights into the understanding of the pathophysiology of this disease and new
therapeutic concepts with reasonably designed antioxidant approaches is a necessity.
The protective effects of FGFs in the context of oxidative stress have been well
documented

45-49, 58-60

. On the other hand, under pathological conditions such as DN,

there are reports of upregulation of bFGF

32

. Concomitantly, some studies have shown

that aFGF is upregulated by oxidative stress 66. This evidence suggests that the increase
in expression of FGFs could be an adaptive response to protect the tissues against
oxidative stress. Alternatively, FGFs are also implicated in pathological conditions such
as tumorigenesis and metastasis due to their potent mitogenic activity. However, the
use of modified forms of FGFs, including maFGF in order to annul its mitogenic function
have been tested in several studies that demonstrate they can keep its vasodilator and
survival actions 38, 55, 57-61.
In the context of diabetes, studies done by us and others have revealed protective roles
of bFGF and aFGF in the hearts of type 1 diabetic mouse models

61, 67

. Moreover, recent

work has demonstrated that both aFGF and a non mitogenic form of aFGF (maFGF) that
lacked oncogenicity, showed similar protective effects on diabetic cardiomyopathy

61

.

This protection is thought to be mediated by suppression of oxidative stress and
damage. With this perspective, we examined if maFGF may induce protection in DN.
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Thus, we investigated such effects using a variety of approaches ranging from
biochemical to structural and functional studies. We employed a type 1 diabetes mouse
model and cell lines exposed to high glucose for the identification of possible
mechanisms.
4.1.2 Prevention of DN by maFGF is probably mediated by attenuation of oxidative
stress.
In the present study, the DN was established in low-dose STZ-induced type 1 diabetic
mouse models, which were examined at 1 month and 6 months. The diabetic mice
showed significant renal dysfunction as evidence by increased albuminuria. We showed
for the first time that maFGF treatment significantly prevented renal dysfunction at both
time points.
DN is considered to be in large part a glomerular disease that is identified by the
development of functional and morphologic abnormalities secondary to hyperglycemia
67

. It is postulated that oxidative stress plays a key role in the sequence of events

accompanying development of glomerular and renal injury

15, 16

. Hyperglycemia triggers

increased production of ROS in renal cells that surpasses the local antioxidant capacity,
which in normal conditions would keep the oxidative balance. This imbalance between
ROS and antioxidants results in harmful effects in renal cells, causing changes in cellular
function and eventually cell death.
Here, we demonstrated diabetes- induced upregulation of HO1 mRNA, a marker of
oxidative stress, and increased activity of the antioxidant enzymes Catalase and
Glutathione peroxidase. All such abnormalities were prevented by maFGF treatment.
Our results are consistent with studies that have shown that Glutathione peroxidase and
Catalase mRNA expression and activities are increased under conditions of high glucose
and in the renal cortex of diabetic rats

68, 69

, corresponding with increased oxidative

stress. However, decreases in expression and sometimes in the activities of antioxidants
enzymes such as superoxide dismutase (SOD) have been reported in DN 15, 70. Reduced
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antioxidant capacity is also one of the causes that lead to increased oxidative stress in
diabetic conditions. Although we did not assess the activity of SOD enzymes in this study
maFGF was shown to exert increased activity of superoxide dismutase (SOD) in a model
of ischemia- reperfusion injury in which maFGF showed protective effects in the brain
60

). However maFGF did seem to have a direct effect in the activity of the antioxidant

enzymes assessed in this study. Our findings suggest that some of the observed effects
of maFGF are possibly mediated through a mechanism related to decreasing oxidative
stress.
Since hyperglycemia is thought to be the main cause that produces alterations in
diabetic complications, we performed mechanistic studies exposing HMVEC and
podocytes to high glucose for mimicking diabetes like conditions in vitro. Podocytes and
endothelial cells are closely related in the glomerular filtration barrier. They affect the
behaviour of the glomerular filtration membrane.
Oxidative stress may cause podocyte damage and loss. This represents an early change
in DN related to microalbuminuria and progressive proteinuria; leading to
glomerulosclerosis. Concurrently, endothelial dysfunction occurs and also leads to
glomerulosclerosis

71

. For these studies, we added native or modified aFGF into the

medium of podocytes or HMVEC cell culture to investigate whether aFGF can induce
anti-oxidative effects in these cells under high glucose conditions. The level of ROS and
HO1 were examined in podocytes. We found that both ROS and HO1 mRNA levels were
increased under high glucose conditions and were significantly attenuated by either
native aFGF or maFGF. This implies that anti-oxidative function of aFGF might be the
mechanism to prevent podocyte injury and kidney dysfunction in the context of
diabetes. Similar results were obtained when we assessed the possible protection by
maFGF on endothelial cells. maFGF prevented high glucose-induced upregulation of HO1
expression. This is in keeping with other studies done in our lab demonstrating
attenuation of high glucose induced ROS levels in this cell type 61.
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Increased levels of ROS in the cells initiate an array of damaging reactions which can
damage lipids, proteins, and DNA

15

. Therefore, in the present study we also tried to

determine whether maFGF treatment could protect oxidative DNA damage in kidney
tissues of diabetic animals and endothelial cells exposed to high glucose. We
demonstrated increased positive 8-OHdG staining, a marker of oxidative DNA damage, in
the nuclei of glomeruli cells after 6 months of onset diabetes. The treatment with
maFGF reduced the number of positive cells, suggesting that prevention from oxidative
stress prevents subsequent DNA damage. Similarly, after incubation of HMVEC in high
glucose, increase 8-OHdG staining was evident compared to those under normal
conditions. Nonetheless, maFGF or aFGF prevented such damage indicating that maFGF
protects high glucose-induced oxidative DNA damage in HMVEC. It is to be noted that
the high glucose exposed cells had also higher 8-OHdG stain in the cytoplasm. Exact
reason is not clear. However, possibility that this may represent damaged mitochondrial
DNA cannot be excluded.
4.1.3 Protection of DN by maFGF may be in part through mechanisms involving
prevention of AGT and eNOS alteration which prevent cellular dysfunction.
Under high glucose ambience, a cross talk between metabolic and hemodynamic factors
operates in the kidney. Like the ROS that amplify hyperglycemia injury, increased
glomerular capillary pressure also contributes to the acceleration of diabetes- related
alterations

8, 9, 11-13

. High glucose sensitizes the kidney to pressure-induced damage

which is central to early hyperplasia and late hypertrophy of the renal cells 9. This is
enhanced by ROS generation with upregulation of various vasoactive factors and
cytokines, which is followed by ECM accumulation

72

. Therefore, we tried to identify

whether this protection could have effects in mRNA expression of vasoactive factors and
cytokines in vivo.
We demonstrated that some vasoactive factors such as AGT, VEGF, NO producing
enzymes eNOS and iNOS were significantly upregulated in diabetic animals after 1
month of onset of diabetes. These factors are shown to be associated with
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intraglomerular pressure and increased permeability in the first stages of diabetic
nephropathy 8. The treatment with maFGF prevented upregulation of eNOS and AGT but
failed to prevent upregulation of iNOS and VEGF in this first stage. However, after 6
months of administration of maFGF treatment, prevention of diabetes- induced mRNA
upregulation of the hypertrophic marker AGT was sustained, indicating prevention of
hypertrophy from an early stage. These results were supported by significant prevention
of diabetic-induced increase of kidney weight - tibia length ratio by maFGF treatment
after 6 months. Additionally, after 6 months of administration, maFGF also prevented
diabetes- induced downregulation of VEGF and NO producing enzymes eNOS and iNOS
which are features of advanced DN. Exact reason for such attenuation is not known. It is
possible that in these later stages the levels of such factors decrease, possibly due to
endothelial dysfunction causing the arrest of endothelial growth and inducing apoptosis
8, 9

. Treatment with maFGF could partially protect diabetes-induced molecular levels of

renal damage in the first stages and prevent alteration of these molecular levels at later
stages.
These in vivo findings were confirmed by in vitro studies: both, HMVEC and podocytes
showed significant upregulation in the expression of AGT under high glucose condition,
which was prevented by maFGF treatment at 48 hours. Some evidence revealed that
exposing glomerular endothelial cells and podocytes in culture to high glucose activates
production of AGT 73, 74. AGT is the precursor of angiotensin II (ANG II) and is one of the
components of the renin-angiotensin system (RAS) which could be locally activated in
podocytes and endothelial cells by high glucose. The activation of intracellular RAS
system in these cells is thought to be involved in progression of DN 74. Parallel to this, we
found that maFGF treatment significantly prevented high glucose- induced down
regulation of eNOS mRNA expression in both cell types at 48 hours. In vitro studies done
by others have evidenced that hyperglycemia- induced ROS production reduces eNOS
expression and activity in endothelial cells leading to decreased endothelial cell survival
and endothelial dysfunction

11, 19

. Similarly, eNOS deficiency provokes profound effects

on podocyte integrity and leads to albuminuria

12, 26

. These results suggest that
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treatment with maFGF could protect cellular dysfunction and damage induced by high
glucose in part through mechanisms involving prevention of AGT and eNOS alteration,
although further studies need to be done to elucidate whether this prevention is
secondary of the prevention of ROS production.
4.1.4 The prevention of functional, biochemical and structural changes in DN by maFGF
seems to work through a TGFβ-1 independent pathway
High glucose enhances cellular ROS generation exerting upregulation of various
vasoactive factors and cytokines, which is followed by ECM accumulation

72

. We

detected the mRNA expression of fibrosis markers TGFβ-1, FN and Col 1α (IV) in both in
vivo diabetic mouse model after 1 month and 6 months after onset of diabetes, and in
vitro cultured cell lines exposed to high glucose. We demonstrated up-regulation of
mRNA expression of these fibrosis-related genes in diabetic animals and in both cell
types HMVEC and podocytes exposed to high glucose. During the in vivo study maFGF
showed some preventive effects on alteration of extracellular matrix proteins FN and Col
1α (IV) exhibited by mRNA and protein expression and confirmed by PAS staining,
especially after longer administration. However, the treatment failed to prevent the
induced fibrogenic cytokine TGF-β1. Surprisingly, the in vitro studies showed similar
results with respect to maFGF failing to prevent the fibrogenic cytokine TGF-β1 in both
cell types. Additionally, it failed to prevent the high glucose- induced upregulation of the
ECM proteins FN and Col 1α (IV) in HMVEC, but not in podocytes in which showed
significant prevention.

According to this, maFGF treatment failed to prevent the

fibrogenic factor TGF-β1, although partially prevented diabetes-induced upregulation of
extracellular matrix proteins. TGF-β1 is known to be the main mediator of the
abnormalities of DN, as it is a key regulator of ECM protein synthesis and responsible for
apoptosis in podocytes and fibroblasts proliferation

75, 76, 77

. The results obtained in this

study show that diabetes- induced damage and biochemical and structural changes in
kidneys are attenuated by maFGF and that such process may work through a TGF- β1
independent pathway

20, 46, 50, 54, 78

. Current studies in our lab have shown the
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involvement of other upstream mediators of FN expression in diabetes

79, 80, 81

. The

vasoactive factor endothelin 1 (ET-1), which is upregulated in DN, mediates expression
of ECM proteins such as FN via NF-κB and AP-1 (activating protein 1) activation79.
Furthermore, the transcriptional coactivator p300, which is induced by diabetes in target
organs including the kidneys, is involved in the regulation of gene expression of
vasoactive factors and ECM proteins in DN

80, 81

. This transcription factor also interacts

with NF-κB in mediating FN expression. The fact that TGF-β1 mRNA upregulation was
not prevented by the maFGF treatment but ECM expression was partially prevented
mainly through prevention of FN protein expression suggest that maFGF may exert its
prevention through interacting with transcription factors such as the aforementioned
ones. Further studies to elucidate this mechanism are needed.
4.1.5 The preventative effect of maFGF treatment in DN probably involves stimulation
of eNOS activity towards production of NO and stimulation of antiapoptotic genes
expression such as Bcl-2.
The protective effects of maFGF treatment in DN, as comparable to native aFGF, may be
the result of vasodilation, antioxidant, anti-inflammatory and antiapoptotic functions of
FGFs. Several studies, including ours, reveal protection of FGFs against oxidative stress in
different models including diabetic complications 61, 67, 78, ischemia- reperfusion injury 56,
60

or direct induction of oxidative stress 58, 59. Some mechanisms have been proposed to

elucidate these pleiotropic effects including the activation of PI3 K/Akt and ERK1/2
pathways

20, 46

, or the implication of FGFs on lipids metabolism

54, 78

. With the same

perspective, some studies reveal the activation of eNOS enzyme and the production of
NO by FGFs 50-54, linking this effect with the vasodilator and antiapoptotic functions.
Alternatively, evidence shows that production of superoxide may cause uncoupling of
eNOS leading to production of superoxide anion rather than NO 15, 20-23 which is known
to play a key role in vascular homeostasis. Our results demonstrated that maFGF causes
prevention of oxidative stress in vivo and in vitro, as well as corrects the deficit of eNOS
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enzyme expression. Therefore, we tried to identify whether maFGF has any effects in NO
production in vivo and in vitro as indication of eNOS activation in a coupled state.
We demonstrated that diabetic-induced decrease of NO production was concomitant
with the down regulation of eNOS enzyme in later stages of DN. The treatment with
maFGF significantly increased NO production. These findings were confirmed in vitro
showing that in both cell types HMVEC and podocytes, maFGF significantly restored the
high-glucose induced decrease production of NO. Furthermore, similar results were
obtained when these cells were treated with L-NAME, an eNOS inhibitor, showing that
maFGF similar to aFGF, exerts activation of eNOS in a coupled state. In spite of using LNAME NO levels were not completely abolished. Exact reason is not evident. Potential
explanation may be in the specific system used in this study which showed higher basal
levels. These results may suggest that some of the beneficial effects of maFGF in DN
could be through activation of eNOS in a coupled state with subsequent production of
NO that restores the deficit of NO and therefore preventing cell dysfunction. Moreover,
maFGF would prevent uncoupled eNOS- induced ROS production (Figure 4.1).
Interestingly, evidence in support of the importance of high glucose induced- ROS and
oxidative DNA damage in mediating apoptosis is reflected in our in vitro studies that
show reduced antiapoptotic- proapoptotic Bcl-2/Bak-1 ratio mRNA expression in HMVEC
and podocytes exposed to high glucose. Numerous studies show that aFGF and maFGF
plays a key role in the prevention of cell death

48, 49, 55, 56

. The treatment with maFGF

significantly restored the reduction of Bcl-2/Bak-1 ratio comparable with aFGF. These
results were confirmed with TUNEL assay in kidney tissues that showed maFGF
prevention of increased TUNEL positive cells observed in diabetic animals. Further
correlation studies could establish an association between the ability of maFGF to
activate the activity of eNOS towards the production of NO and the preventative effects
of maFGF against oxidative stress, apoptosis, and subsequent biochemical and structural
changes, and functional damage prevention. In addition, assessment of effects of maFGF

73

treatment in nitrosative stress is essential since ONOO- formation is potentially a major
pathway governing NO reactivity 17, 82.

74

Figure 4.1 Scheme depicting proposed mechanism underlying prevention of DN by
maFGF treatment. High glucose induces increase production of ROS which reacts with
NO to form the potent oxidizing species peroxynitrite (ONOO-). The oxidation of eNOS
cofactor BH4 decreases availability which, in addition to the oxidation of eNOS zincthiolate cluster, leads to eNOS uncoupling which produce ROS rather than NO. The
activation of eNOS in a coupled state by maFGF prevents production of ROS and restores
NO deficiency. The questions marks indicate further studies that need to be done to
elucidate the exact mechanism of eNOS activation by maFGF. Other potential pathways
that may additionally contribute to attenuation of ROS such as prevention of AGT mRNA
expression need further clarification (Figure adapted from reference # 83).
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Finally, our findings show that maFGF prevents 1) functional damage and biochemical
and structural changes in DN, 2) oxidative stress and oxidative DNA damage in DN, 3)
diabetic-induced apoptosis in kidneys and high glucose-induced apoptosis in HMVEC and
podocytes, 4) deficient NO production in kidney tissues of diabetic animals and in
MHVEC and podocytes under high glucose conditions. These results suggest that the
preventative effect of maFGF treatment in DN is probably mediated by attenuation of
renal oxidative stress, stimulation of eNOS expression and activity in a coupled state that
leads to increased levels of NO production and stimulation of expression of
antiapoptotic genes such as Bcl-2. It is important to emphasize that, in these studies,
maFGF showed a similar anti-oxidative and antiapoptotic capacity to native aFGF
underscoring the possible advantage of maFGF for clinical implications. maFGF does not
have mitogenic action as demonstrated before 55, 57 and therefore would lack oncogenic
effect compared to the native aFGF. These results are also concomitant with previous
studies done with maFGF and its effects in diabetic cardiomyopathy
potential therapeutic role of maFGF in DN.

61

. This indicates a

76

4.2 Future directions
We have shown the protective effects of maFGF in DN in a type 1 diabetic mouse
model and in high glucose-induced changes of two cells types present in the kidneys,
namely: HMVEC and podocytes, which are part of the integrative filtration barrier. To
further establish the protective effects of maFGF in DN, the assessment of the role of
maFGF in inflammation and lipid metabolism in DN would be suggested. Similarly, the
use of a type 2 diabetic mouse model could be of interest to study the involvement of
FGF in DN- induced changes in the context of insulin resistance. Some studies have
previously shown that FGF21 and FGF1 play an important role in glucose homeostasis as
insulin sensitizers

75, 78

. Hence, enhancing its benefits as a potential therapy to avoid

diabetic complications would be useful.
In vitro studies with other cell types present in the kidneys could also be considered.
Advance identification of the effects of maFGF in the pathophysiology of diabetic
glomerulopathy would require studies with mesangial cells which are also part of the
filtration barrier

79

. Additionally, the same approach for the study of epithelial tubular

cells and fibroblasts is recommended since high glucose- induced signalling
abnormalities in these cells probably contributes to progressive fibrosis and can induce
epithelial- to- mesenchymal transition in DN 12.
FGFs are pleiotropic peptides and can exert a variety of actions in the cells. Identification
of other activated downstream pathways of maFGF or interaction with other cellular
molecules in the regulation of high-glucose induced cellular alterations would be
necessary to uncover new mechanisms. Finally, in an attempt to further understand the
involvement of native aFGF, mechanisms regulating its production may further need to
be clarified. In any chronic diseases, possible impact of epigenetic mechanisms, which
may regulate such expressions, may need further experiments. It is important to point
out that in some recent studies intricate relationship of FGF with microRNAs and
epigenetic mechanisms have been demonstrated

84, 85, 86, 87

. A better understanding of

such mechanisms will help open up the possibility of using maFGF in DN or other chronic
diabetic complications.
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